Cargando…

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing

PURPOSE: To investigate the HER2 status and clinicopathological features in invasive breast cancer with HER2 ≥4.0 and <6.0, which has always been controversial. METHODS: Forty breast cancer cases with HER2 ≥4.0 and <6.0 by fluorescence in situ hybridization (FISH) were collected and classified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Qianming, Lv, Hong, Bao, Longlong, Yang, Yu, Zhang, Xin, Chang, Heng, Xue, Tian, Ren, Min, Zhu, Xiaoli, Zhou, Xiaoyan, Yang, Wentao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406110/ https://www.ncbi.nlm.nih.gov/pubmed/37554155 http://dx.doi.org/10.2147/BCTT.S420738

Ejemplares similares

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014)

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
por: Slembrouck, Laurence, et al.
Publicado: (2019)

Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Blumencranz, Peter, et al.
Publicado: (2023)

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
por: Espinel, C. Francisco, et al.
Publicado: (2012)

Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
por: Fatima, Areej, et al.
Publicado: (2017)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Myburgh, Ettienne J., et al.
Publicado: (2021)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Lee, Young Joo, et al.
Publicado: (2021)

RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Mansani, Fabio Postiglione, et al.
Publicado: (2022)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Hwang, Young Sol, et al.
Publicado: (2022)

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction
por: Yao, Kevin, et al.
Publicado: (2022)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test()
por: Mittempergher, Lorenza, et al.
Publicado: (2020)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
por: Pan, Bo, et al.
Publicado: (2023)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
por: Zhou, Shuling, et al.
Publicado: (2023)

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
por: Myburgh, Ettienne J., et al.
Publicado: (2016)

Turbo Pascal con aplicaciones 4.0-6.0
por: Hennefeld, Julien O.
Publicado: (1992)

3D printing in materials manufacturing industry: A realm of Industry 4.0
por: Tamir, Tariku Sinshaw, et al.
Publicado: (2023)

Additive manufacturing: expanding 3D printing horizon in industry 4.0
por: Prashar, Gaurav, et al.
Publicado: (2022)

BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance
por: Kuilman, Midas M., et al.
Publicado: (2022)

Deep Learning for Industrial Computer Vision Quality Control in the Printing Industry 4.0
por: Villalba-Diez, Javier, et al.
Publicado: (2019)

Stedman's Plus Spellchecker 4.0
por: Chen, Jersey
Publicado: (1998)

Mamma Roma
por: Pasolini, Pier Paolo, 1922-1975
Publicado: (1965)

Mamma Succenturiata
por: Duncan, Matthews
Publicado: (1873)

Undeveloped Mammæ
por: Mask, W. B.
Publicado: (1894)

Mamma [popular Italian songs /
Publicado: (1984)

Impact of multi-lattice inner structures on FDM PLA 3D printed orthosis using Industry 4.0 concepts
por: Barbosa, William S., et al.
Publicado: (2022)

Sarcoma of Female Mamma
por: Beatson, George Thomas
Publicado: (1909)

Cannot write session to /tmp/vufind_sessions/sess_6af1528g21367mlsd0r63o4em8